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trans-fatty acids (TFAs) are a well-known risk factor of ischemic heart disease (IHD). In Aus-
tralia, the highest TFA intake is concentrated to the most socioeconomically disadvantaged
groups. Elimination of industrial TFA (iTFA) from the Australian food supply could result in
reduced IHD mortality and morbidity while improving health equity. However, such legisla-
tion could lead to additional costs for both government and food industry. Thus, we
assessed the potential cost-effectiveness, health gains, and effects on health equality of an
iTFA ban from the Australian food supply.
Methods and findings
Markov cohort models were used to estimate the impact on IHD burden and health equity,
as well as the cost-effectiveness of a national ban of iTFA in Australia. Intake of TFA was
assessed using the 2011–2012 Australian National Nutrition and Physical Activity Survey.
The IHD burden attributable to TFA was calculated by comparing the current level of TFA
intake to a counterfactual setting where consumption was lowered to a theoretical minimum
distribution with a mean of 0.5% energy per day (corresponding to TFA intake only from non-
industrial sources, e.g., dairy foods). Policy costs, avoided IHD events and deaths, health-
adjusted life years (HALYs) gained, and changes in IHD-related healthcare costs saved
were estimated over 10 years and lifetime of the adult Australian population. Cost-effective-
ness was assessed by calculation of incremental cost-effectiveness ratios (ICERs) using
net policy cost and HALYs gained. Health benefits and healthcare cost changes were also
assessed in subgroups based on socioeconomic status, defined by Socio-Economic
Indexes for Areas (SEIFA) quintile, and remoteness. Compared to a base case of no ban
and current TFA intakes, elimination of iTFA was estimated to prevent 2,294 (95% uncer-
tainty interval [UI]: 1,765; 2,851) IHD deaths and 9,931 (95% UI: 8,429; 11,532) IHD events
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over the first 10 years. The greatest health benefits were accrued to the most socioeconomi-
cally disadvantaged quintiles and among Australians living outside of major cities. The inter-
vention was estimated to be cost saving (net cost <0 AUD) or cost-effective (i.e., ICER <
AUD 169,361/HALY) regardless of the time horizon, with ICERs of 1,073 (95% UI: domi-
nant; 3,503) and 1,956 (95% UI: 1,010; 2,750) AUD/HALY over 10 years and lifetime,
respectively. Findings were robust across several sensitivity analyses. Key limitations of the
study include the lack of recent data of TFA intake and the small sample sizes used to esti-
mate intakes in subgroups. As with all simulation models, our study does not prove that a
ban of iTFA will prevent IHD, rather, it provides the best quantitative estimates and corre-
sponding uncertainty of a potential effect in the absence of stronger direct evidence.
Conclusions
Our model estimates that a ban of iTFAs could avert substantial numbers of IHD events and
deaths in Australia and would likely be a highly cost-effective strategy to reduce social–eco-
nomic and urban–rural inequalities in health. These findings suggest that elimination of iTFA
can cost-effectively improve health and health equality even in countries with low iTFA
intake.
Author summary
Why was this study done?
• Intake of trans-fatty acids (TFAs) is a well-known risk factor of ischemic heart disease
(IHD), and several countries have implemented strategies with mandatory limits of
TFAs in foods.
• In Australia, intake of TFAs is on average low but does not appear to have decreased in
the last decades and is high in certain groups.
• A legislative ban to eliminate industrial TFAs (iTFAs) from the Australian food source
is a plausible strategy to reduce disease burden and health inequality.
What did the researchers do and find?
• We modelled the estimated health effects, costs, cost-effectiveness, and impact on health
equality of a nationwide ban of iTFAs in Australia.
• Over the lifetime of the adult population, around 40,000 IHD deaths could be prevented,
and about 100,000 health-adjusted life years could be gained.
• The ban was estimated to be cost saving (net cost<0 AUD) or highly cost-effective and
could reduce health inequalities in the first 10 years after implementation.
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What do these findings mean?
• A legislative mandatory limit of iTFA in Australian foods was estimated to be a cost-
effective strategy to reduce IHD and related deaths and healthcare costs.
• Socioeconomically disadvantaged groups and Australians outside major cities could
potentially have the greatest health gains from such legislation.
• Our model estimates suggest that even in countries like Australia where intake is low,
elimination of iTFAs can improve public health and health equality.
Introduction
Ischemic heart disease (IHD) is the single most common cause of death in Australia, contrib-
uting to 12% of all deaths in 2016 [1]. A well-known dietary risk factor of IHD is intake of
trans-fatty acids (TFAs), a group of unsaturated fatty acids with 1 or more double bonds in the
trans configuration. TFA causes cardiometabolic dysfunction [2], and a meta-analysis of pro-
spective studies reported that for every 2% of total energy from TFAs, IHD risk increased by
23% [3]. TFAs occur naturally at low levels in meat and milk from ruminants, but in most
countries, intakes are predominantly driven by the use of partially hydrogenated vegetable oils
in processed foods such as pastries [4].
Given the adverse effects of TFAs, the World Health Organization (WHO) recommends
limiting TFA intake to 1 energy percent (%E), and countries have implemented strategies to
reduce industrial-derived TFA (iTFA) in the food supply such as partially hydrogenated vege-
table oils [5,6]. These policies range from voluntary reformulation, mandatory labelling,
through to banning iTFA entirely. For example, iTFA content in foods must be�2% of total
fat in Denmark [7], and in 2015, the United States Food and Drug Administration determined
that partially hydrogenated oils are no longer considered generally recognized as safe for use
in human food [8]. In Australia, voluntary reformulation, encouraged by the government and
other health bodies, led to a reduced intake of iTFA mainly due to the reformulations of edible
oil spreads by leading manufactures prior to 2000 [9,10]. However, between 2005 and 2013,
there was no appreciable further reduction of iTFA in the Australian food supply [10]. Accord-
ing to the latest nationally representative dietary survey conducted in 2011 to 2012, Australians
on average have intakes of TFA at 0.6% of daily energy, with an estimated 60% to 75% coming
from ruminant (natural) sources and the rest being iTFA [10]. However, there is substantial
variability around the average intake, with about 1 in 10 Australians estimated to exceed the
WHO-recommended level of 1%E, especially those in the most socioeconomically disadvan-
taged groups [11]. Our prior modelling suggests that at a current level of intake, TFA continues
to contribute to around 500 deaths per year in Australia, with the majority of these expected to
accrue to those with less education and income [12].
A recent systematic review suggests that, not surprisingly, of all policy approaches currently
implemented around the world to reduce iTFA, bans are the most effective [13]. Despite being
comparatively low, the uneven distribution of consumption means that a part of the popula-
tion consumes TFA in harmful quantities, and TFA intake levels in Australia continue to con-
tribute to the IHD burden [12]. Further removal of iTFA from the food supply through
mandatory limits (iTFA ban) could have additional benefits in Australia and other countries
with similarly low TFA intake but no mandatory limits of iTFA content in foods. To our
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knowledge, Australia has so far not considered a ban of iTFA. In order to further inform policy
regulations related to iTFA in Australia, we conducted a modelling study that estimated the
public health impact and cost-effectiveness of a national ban of iTFAs in Australia, considering
both policy costs and reduced IHD burden and healthcare expenditures. Furthermore, we
investigated whether the greatest benefits would be among the most disadvantaged groups of
the Australian population. Apart from differences across socioeconomic groups, we estimated
benefits separately in groups based on remoteness, given that Australians outside of metropoli-
tan areas often have higher disease burden and poorer access to healthcare and diet compared
to those living in major cities [14,15]. We hypothesized that a ban of iTFA in the food supply
would be a cost-effective measure to reduce IHD burden and health disparities in Australia.
Methods
This study is reported as per the Consolidated Health Economic Evaluation Reporting Stan-
dards (CHEERS) guideline (S1 Checklist). The initial study proposal is presented in S1 Text.
Study design
We used a multiple cohort proportional multistate life table (Markov) model to estimate the
impact on health outcomes and related costs of a complete ban of iTFAs from the Australian
food supply. The ban would cover all foods and ingredients containing iTFA and therefore tar-
get both packaged and restaurant foods. Our model was constructed to calculate IHD-related
outcomes and total healthcare costs resulting from the intervention [12,16]. The life table
method transmits changes in iTFA intake to IHD-related morbidity and mortality in the mod-
elled population. The analysis was conducted for the total Australian population and for pre-
specified subpopulations: socioeconomic quintiles defined according to the Index of Relative
Socio-Economic Disadvantage of the Socio-Economic Indexes for Areas (SEIFA) [17]; and
inhabitants of major cities, inner regional Australia, and other regional areas (including outer
regional, remote, and very remote Australia). We initially planned to evaluate the health
impact of the ban stratified by Aboriginal status (S1 Text) but could not reliably estimate age-
and sex-specific distributions due to small sample sizes. In all analyses, adults (age�20 y) were
modelled in 5-year male and female cohorts, simulating each cohort until all individuals died
or reached 100 years of age. Outcomes were compared between a reference population with
TFA intake of the Australian population before the intervention and an intervention popula-
tion with identical characteristics but lower TFA intake that is expected after the elimination
of iTFAs from the food supply. The difference in health outcomes between reference and inter-
vention populations were expressed in IHD incidence and deaths, life years, and health-
adjusted life years (HALYs). Results were reported for 10-year and life span (i.e., the time from
policy implementation until all individuals died or reached 100 years of age) time horizons.
We used an ‘extended’ health sector perspective that included costs of legislation and industry,
as these are directly related to the intervention. Costs were adjusted to 2010 values, and in line
with the recommendations of the first and second panels on cost-effectiveness in health and
medicine, we used a 3% discount rate in the main analysis [18,19].
Data sources
Intake of TFA in Australia. As previously described [12], nationally representative
intakes of TFA were assessed using the 2011–2012 Australian National Nutrition and Physical
Activity Survey (NNPAS) [20]. Baseline intake of TFA as %E was calculated per age and sex
group in the total population; by remoteness of residence (major cities, inner regional areas,
and outer regional areas); and by socioeconomic status in individuals belonging to each
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socioeconomic quintile defined according to SEIFA (S1 Table). A mandatory ban in Denmark
virtually eliminated iTFA from the food source [21]. Thus, we assumed the post-intervention
TFA intake of all sex-age groups to be equal to the theoretical minimum risk distribution, i.e.,
0.50 ± 0.05%E in our primary model (Table 1), based on the likely average intake of nonindus-
trial-derived TFAs (i.e., from meat and dairy from ruminant animals) [12,22].
Health outcomes. Estimates of total and subgroup-specific population demographics,
mortality rates, and IHD burden (prevalence, incidence, and mortality) were based on data
from the Australian Bureau of Statistics, the Australian Institute of Health and Welfare
(AIHW), and the Global Burden of Disease project (Table 1). Our model included adults aged
20 to 100 y; 51% of the total model population were women, 68% lived in major cities, 18% in
inner regional Australia, and 11% in outer regional, remote, or very remote areas. Age-specific
relative risks of TFA intake and IHD were based on meta-analyses of findings from prospective
cohort studies [23]. Children and adolescents (age <20 y) were not included in the model,
given the low IHD burden and the lack of well-established relative risks of TFA intake and
IHD in that age group.
Healthcare and policy costs. Healthcare costs related to IHD treatment including
hospital services, out-of-hospital medical services, pharmaceuticals, and health professionals
were based on Disease Costs and Impact Study (DCIS) 2001 data from the AIHW, inflated
to 2010 prices using AIHW health price inflation values [24]. Healthcare costs for diseases
and injuries unrelated to IHD due to additional years of life gained were also taken from the
DCIS.
The policy costs estimated for an elimination of iTFA in Australia included costs for gov-
ernment (i.e., legislation and monitoring costs) and industry (i.e., initial and ongoing reformu-
lation as well as product labelling costs). Legislation costs were estimated as described in detail
by Lal and colleagues, using a costing framework for public health legislation including parlia-
mentarians’ time, annual expenses for the House of Representatives and the Senate, legislation
drafting and publication, and policy advice [25]. In the absence of Australian estimates for
TFA monitoring and reformulation costs, we utilized United Kingdom estimates (annual cost
of £2.4 million [26]) to calculate equivalent Australian dollar costs of TFA monitoring, while
adjusting for population size differences between the countries (i.e., multiplying with the ratio
of 0.35, derived from dividing the Australian (22.3 million) by the UK population (63.3 mil-
lion)). Reformulation costs were calculated using equivalent Australian dollar costs from UK
estimates (£25,000 per product [26]) multiplied by the number of products in the Australian
food supply potentially containing iTFA. We estimated this number by identifying products in
the 2018 Australian FoodSwitch database [27] that contained any terms indicative of iTFA in
the ingredient list (i.e., ‘partially hydrogenated fat’, ‘hydrogenated vegetable oil’, or ‘hydroge-
nated’) [28]. Of 28,349 foods included in the analysis, 131 products (0.5%) contained specific
ingredients indicative of iTFA [28]. As the intervention could lead to increased costs to indus-
try for changes in packaging and loss through disuse of existing packaging, we estimated a
1-time repackaging cost as 10% of reformulation costs [26]. In line with previous modelling
studies [26,29], we assumed an ongoing annual industry cost of equalling 1% of the initial
reformulation cost to conservatively account for reduced industry profits.
Statistical analysis
Estimation of health benefits and cost-effectiveness. The reference and intervention
TFA intakes and the relative risk of IHD per %E of TFA intake were used to calculate the
potential impact fraction (PIF) for estimation of the proportional change in IHD incidence
due to the elimination of iTFAs (Eq (1)). Barendregt’s continuous ‘distribution shift’ PIF
PLOS MEDICINE Estimated cost-effectiveness of transfat elimination in Australia
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003407 November 2, 2020 5 / 19
Table 1. Data sources for modelling.
Input Stratification Values Source Note
Pre-intervention TFA
intake, %E
Age, sex See S1 Table 2011–2012 NNPAS For subgroups1, weighted mean and standard
deviations from 2011–2012 NNPAS were
assumed to approximate nationally representative




n/a Mean ± SD: 0.50 ± 0.05
(primary analysis)
Mean ± SD: 0.4 ± 0.04
(sensitivity analysis)
Wu et al., Nutrients, 2017
Allen et al., BMJ, 2015
Theoretical minimum
risk distribution of TFA
intake, %E
n/a Mean ± SD: 0.50 ± 0.05
(primary analysis)
Mean ± SD: 0.4 ± 0.04
(sensitivity analysis)
Wu et al., Nutrients, 2017
RR for CHD per 2%E
from TFA
Age 25–34 y: 1.42 (1.28–
1.57)
35–44 y: 1.40 (1.27–
1.54)
45–54 y: 1.33 (1.22–
1.45)
55–64 y: 1.27 (1.18–
1.36)
65–74 y: 1.22 (1.15–
1.29)
�75 y: 1.16 (1.11–1.21)
Wang et al., JAHA, 2017 For each model iteration, random draws from
age-specific lognormal RR distributions were
made.
Population size Age, sex See S2 Table ABS report 3101.0 –Australian Demographic
Statistics, December 2010 –TABLE 59.
Estimated Resident Population By Single
Year Of Age, Australia.










See S2 Table ABS 2011 Census of Population and Housing,






See S3 Table Mortality inequalities in Australia 2009–2011
Table S3.1: Deaths by socioeconomic group,
by sex, and by age group, 2009–2011
Mortality rates in each remoteness or
socioeconomic subgroup were available per sex in
5 specific age groups (15–24 y, 35–44 y, 45–64 y,
65–84 y, and 85+). Mortality rates for each
subgroup-, sex-, and year of age-stratum was
calculated by multiplying sex- and year of age-
specific mortality rate in the total population with
the ratio of the subgroup-specific mortality rate







See S4 and S5 Tables AIHW Cardiovascular disease web pages data
tables3
IHD incidence for each subgroup-, sex-, and age-
stratum was calculated by multiplying sex-age-
specific IHD incidence in the total population
with the ratio of the subgroup-specific CVD
hospitalisation rate and the age-adjusted CVD
hospitalisation rate of the total population.
Subgroup-, sex- and age-specific IHD prevalence
was calculated similarly.
Disability weights Sex Male: 7.67%
Female: 7.63%
Global burden of disease project 20104 Weighted average of MI, angina, and heart failure
Healthcare costs Sex, age See S5 Table AIHW 2001 inflated to 2010 Total and IHD-related healthcare costs were
estimated separately.
(Continued)
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The PIFas is the potential impact fraction for age group a and sex s, RRa(x) is the relative
risk as a function of the exposure x (i.e., TFA intake), Pas(x) is the reference TFA intake distri-
bution, and P’as(x) is the intervention TFA intake distribution. The PIF was used to calculate
the effect on IHD incidence due to the reduction in TFA intake (Eq (2)).
I0 ¼ Ið1   PIFÞ ð2Þ
I is the IHD incidence in the reference population, I’ is the IHD incidence in the interven-
tion population, and PIF is the potential impact fraction. The estimated incidence rates were
used in life tables to calculate reference and intervention IHD prevalence and mortality. To
account for time spent in suboptimal health due to IHD and any other conditions present, we
calculated HALYs. Each year of life lived was adjusted using all-cause ‘prevalent years lived
with disability’ values from the Global Burden of Disease 2010 study. These sum the loss of dis-
ease-related quality of life by age based on prevalence and disability weight for all conditions
Table 1. (Continued)
Input Stratification Values Source Note
Legislation costs n/a Mean ± SD:
1,090,000 ± 77,497
AUD
Lal et al., PLoS Med., 2017 For each model iteration, a random draw from a
gamma distribution of legislation costs was made.
Monitoring cost n/a 1,557,422 AUD/year Allen et al., BMJ, 2015 Monitoring costs were estimated using equivalent
Australian dollar costs (2011 exchange rate: 1.84
AUD/GBP) of UK estimates (annual cost of 2.4
million GBP), while adjusting for 2011
population size differences between the UK (63.3







Allen et al., BMJ, 2015 and Huang et al.,
ANZJPH, 2020
Reformulation costs were calculated using
equivalent Australian dollar costs (2011 exchange
rate: 1.84 AUD/GBP) from UK estimates (25,000
GBP per product) multiplied by the number of
products in the Australian food supply potentially
containing iTFA (primary model: n = 131;







Allen et al., BMJ, 2015 Annual cost to industry equalling 1% of the initial
reformulation cost was assumed.
Initial industry
repackaging




Allen et al., BMJ, 2015 Increased costs to industry for changes in
packaging and loss through disuse of existing
packaging were estimated as a 1-time cost to 10%
of reformulation costs.
ABS, Australian Bureau of Statistics; AIHW, The Australian Institute of Health and Welfare; AUD, Australian dollar; CHD, coronary heart disease; CVD, cardiovascular
disease; %E, energy percentage; GBP, British pound; IHD, ischemic heart disease; iTFA, industrial TFA; NNPAS, National Nutrition and Physical Activity Survey; RR,
relative risk; SD, standard deviation; SEIFA-IRSD, Socio-Economic Indexes for Areas–Index of Relative Socio-Economic Disadvantage; TFA, trans-fatty acid; UK,
United Kingdom.
1URL: https://www.ausstats.abs.gov.au/ausstats/subscriber.nsf/0/F773BDC941982EF5CA257943000CFD5D/$File/33020_2010.pdf (Accessed September 10, 2019).
2Subgroups includes: socioeconomic status (defined by SEIFA-IRSD quintiles), and remoteness (major city; inner regional, and outer regional/remote/very remote).
3URL: https://www.aihw.gov.au/getmedia/0c4fd299-edc6-40f5-b5e1-69d48c9c9648/cvd-ccc2016-20409.xls.aspx (Accessed July 25, 2019).
4Salomon et al., Lancet., 380(9859):2129–2143.
https://doi.org/10.1371/journal.pmed.1003407.t001
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(Table 1). One HALY thus represents the equivalent of a year in perfect health. HALYs gained
were calculated as the difference in HALYs between the reference and intervention popula-
tions. Changes in healthcare expenditures were estimated both for IHD-related healthcare and
total healthcare. The change in IHD-related healthcare expenditure was based on the predicted
reduction in IHD mortality and morbidity. Overall healthcare costs in added years of life were
also included [31].
Net costs included policy costs and healthcare costs (including costs unrelated to IHD) and
were utilized to calculate the incremental cost-effectiveness ratios (ICERs), defined as the dif-
ference in net costs of the intervention compared to current practice, divided by the difference
in HALYs. We initially planned to use WHO benchmarks for definition of cost-effectiveness
(S1 Text) but decided to use an Australia-specific definition instead where cost-effectiveness
was defined as ICER< Australian dollar (AUD) 169,361 per HALY gained (i.e., the value of a
statistical life year in 2007 [32], inflated to 2010 using consumer price index [33]). Cost saving
was defined as a negative net cost.
Subgroup analyses
For each prespecified subgroup (i.e., SEIFA quintiles and areas of residence), subgroup-spe-
cific models were created by substituting key input parameters (i.e., IHD incidence, mortality
rate, TFA intake, and population number) with subgroup-specific data (Table 1).
Health inequalities were estimated by comparing HALYs gained in extreme SEIFA quintiles
and by using SEIFA quintiles to calculate concentration indices [34]. The concentration index
quantifies the distribution of HALY over socioeconomic quantiles and takes a negative value
when HALYs gained are disproportionally concentrated in the most disadvantaged groups
[34].
Uncertainty and sensitivity analysis
The parameter uncertainty around the modelled estimates was quantified using Monte Carlo
simulations (n = 2,000). For each iteration, a draw was made from the distributions of TFA
intake, relative risks, and legislation costs. The point estimate and 95% uncertainty intervals
(UI) were defined as the 50th and 2.5th to 97.5th percentiles, respectively, of the distribution of
the intervention effects (e.g., HALYs gained) estimated across all 2,000 iterations using the
Ersatz version 1.35 software (Epigear International, Sunrise Beach, Australia). Similarly,
Monte Carlo simulations (n = 2,000) of policy costs were conducted in RStudio version
1.1.423 (Boston, Massachusetts, USA).
Univariate sensitivity analysis was used to explore the impact of variation in discount rates
(0% and 6%), theoretical minimum risk distribution, and TFA exposure. We assumed a lower
post-intervention intake and theoretical minimum risk distribution, both with mean of 0.4%E
[26], i.e., the estimated maximum level of TFA from ruminant sources in the UK, and 0.04%E
as standard deviation (i.e., 10% of the mean). We also evaluated the impact of higher post-
intervention intakes (e.g., due to suboptimal compliance to the ban or lower contribution of
iTFA to total TFA) with greater mean (0.52%E to 0.60%E) and with standard deviations equal
to 10% or 50% of the mean. We also evaluated the impact of lower pre-intervention intakes,
with the post-intervention mean intake of the primary model (i.e., 0.50%E) but only half the
difference between the pre- and post-intervention mean intakes. In order to test the effect of a
potentially greater prevalence of iTFA in Australian foods (e.g., due to TFA-containing restau-
rant foods not included in the FoodSwitch database), the number of products potentially con-
taining iTFA was assumed to be twice as many as identified in the FoodSwitch database [28].
Experience of TFA regulations in Denmark has suggested negligible reformulation costs [29],
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and thus we conducted a sensitivity analysis assuming no industry costs. Given the differences
between the UK (from where our assumption for the primary model was based) and Australia
(e.g., geographic dispersion), it is possible that monitoring costs maybe greater per capita in
Australia compared to the UK. Thus, we also evaluated the impact of 25% greater monitoring
costs compared to our primary model.
Results
Overall health gains, costs, and cost-effectiveness
Compared to current levels of TFA intake, a ban of iTFAs was estimated to avert 2,294 IHD
deaths and 9,931 IHD events during the first 10 years, which over the population lifetime (i.e.,
the time from policy implementation until all individuals died or reached 100 years of age)
would amount to 41,877 averted IHD deaths and 56,759 averted IHD events (Fig 1 and
Table 2). The ban was estimated to result in 6,377 HALYs and 5,532 total life years gained
over 10 years; over the population lifetime, 108,321 HALYs and 127,268 total life years would
be gained (Fig 2 and Table 2). During the first 10 years, the per capita total and IHD-related
healthcare costs savings were estimated as AUD 20 and AUD 15 per person, respectively
(Fig 3A and Table 2). Over the population lifetime, AUD 22 IHD-related healthcare cost and
AUD 23 total healthcare cost would be saved per person (Fig 3B and Table 2).
Fig 1. Ischemic heart deaths (A–B) and incidences (C–D) avoidable during the first 10 years (A, C) and over the population lifetime (B, D).
Error bars represent 95% uncertainty intervals. IHD, ischemic heart disease; SEIFA, Socio-Economic Indexes for Areas.
https://doi.org/10.1371/journal.pmed.1003407.g001
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Banning and elimination of iTFA from the Australia food supply was estimated to cost
nearly AUD 22 million during the first 10 years and AUD 56 million over the population life-
time (Table 2), with a majority of estimated costs attributed to government costs for monitor-
ing. During the same time periods, the IHD-related healthcare cost savings, compared to no
ban, were estimated to AUD 80 million and AUD538 million, respectively (Table 2). When
other healthcare costs (i.e., including those related to a greater and older population resulting
from the estimated reduced IHD mortality) were considered, the savings were estimated to
AUD 14 million over 10 years. However, due to reduced IHD mortality resulting in a larger
and older population, it was estimated that the ban would result in AUD157 million additional
healthcare costs over the population lifetime (Table 2). Thus, the net policy costs over 10 years
and the population lifetime were estimated as AUD 7.2 million and 212.9 million, respectively
(Table 2). The elimination of iTFA in Australia was estimated to be cost saving (i.e., net cost
<0 AUD) to highly cost-effective during the first 10 years (1,153 AUD/HALY [95% UI: domi-
nant; 3,578], i.e.,�2% of the value of a statistical life year) and highly cost-effective over the
population lifetime (1,961 AUD/HALY [95% UI: 1,015; 2,756], Table 2).
Effect on health disparities
Over the first 10 years, the iTFA ban, compared to current TFA intake, was estimated to
reduce health inequalities, and the most socioeconomically advantaged quintile had the lowest
proportions of averted IHD deaths (12%) and events (15%); and HALY (14%), as well as life
years gains (12%) compared to other quintiles (Figs 1 and 2). The greatest proportion of
HALYs would accrue to the least advantaged quintiles (Fig 4 and Table 3). For example, the
Table 2. Estimated health gains, costs, and cost-effectiveness of eliminating industrial TFA from the Australian
food supply over 10 years and over the population lifetime.
10 years Estimate (95% UI) Lifetime Estimate (95% UI)
IHD events avoided 9,931 (8,429; 11,532) 56,759 (44,493; 69,358)
IHD deaths avoided 2,294 (1,765; 2,851) 41,877 (32,855; 51,138)
Life years gained 5,532 (4,285; 6,845) 127,268 (106,176; 148,917)
HALYs gained 6,377 (5,151; 7,685) 108,321 (91,187; 125,986)
Change in IHD-related healthcare costs, million AUD 80 (-98; -69) -538 (-628; -463)
Per capita, AUD -15.0 (-18.3; -11.9) -21.7 (-26.0; -17.3)
Change in total healthcare costs, million AUD -14 (-34; 3) 157 (48; 260)
Per capita, AUD -19.7 (-24.5; -15.2) -23.0 (-28.8; -17.5)
Policy costs, million AUD 21.5 (21.3; 21.6) 56.0 (55.9; 56.2)
Governmental costs 14.3 (14.2; 14.5) 47.6 (47.4; 47.7)
Legislation 1.1 (0.9; 1.2) 1.1 (0.9; 1.2)
Monitoring 13.3 46.5
Industry costs 6.6 7.8
Initial reformulation 6.0 6.0
Annual industry costs 0.5 1.8
Repackaging 0.6 0.6
Net costs1, million AUD 7.2 (-12.9; 24.4) 212.9 (104.1; 315.8)
ICER2, AUD/HALY 1,153 (dominant; 3,578) 1,961 (1,015; 2,756)
AUD, Australian dollar; HALY, health-adjusted life year; ICER, incremental cost-effectiveness ratio; IHD, ischemic
heart disease; TFA, trans-fatty acid; UI, uncertainty interval.
1Calculated as the sum of policy costs and change in total healthcare costs.
2Calculated as net costs divided by HALYs gained.
https://doi.org/10.1371/journal.pmed.1003407.t002
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most disadvantaged quintile of the population would gain 742 more HALYs over 10 years,
compared to the most advantaged quintile (Table 3). Similar reductions in health disparity
were observed for healthcare cost savings (Fig 3). Over the population lifetime, the ban was
not estimated to significantly reduce health disparities (Fig 4 and Table 3). Although only 30%
of Australians live outside major cities, around 4 in 10 averted IHD events and deaths, as well
as, HALYs and life years gained were estimated to accrue to this group (Figs 1 and 2). In addi-
tion, they would experience greater healthcare cost saving per capita compared to those living
in major cities (Fig 3).
Sensitivity analyses
For each of the deterministic sensitivity analyses, the iTFA ban was estimated to be cost saving
or highly cost-effective (Fig 5 and S7 Table), with no 95% UI exceeding 20% of the value of a
statistical life year. The greatest ICER during the first 10 years was estimated when assuming
0% discount rate: 3,308 AUD/HALY (95% UI: dominant; 5,970). Assuming the same discount
rate over the population lifetime also suggested that the ban would be highly cost-effective,
with estimated ICER 15,423 (95% UI: 14,176; 16,540). On the contrary, when assuming a 6%
discount rate, the ban was estimated to be cost saving (Fig 5). Assumptions regarding lower
Fig 2. Total (A–B) and HALYs (C–D) gained during the first 10 years (A, C) and over the population lifetime (B, D). Estimates are presented
separately for the total population and selected subgroups. Error bars represent 95% uncertainty intervals. HALYs, health-adjusted life years;
SEIFA, Socio-Economic Indexes for Areas.
https://doi.org/10.1371/journal.pmed.1003407.g002
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pre- or post-intervention TFA intakes, abundance of iTFA-containing products in Australia,
and monitoring or industry costs had minor impact on model estimates (Fig 5). Assumptions
of a less effective elimination of iTFA (i.e., greater post-intervention TFA intake with wider
distribution) resulted in increased ICER, especially over the 10-year horizon (S7 Table). How-
ever, the estimated ICER across all sensitivity analyses were estimated to be<20% of the cost-
effectiveness threshold, i.e., the intervention remained highly cost-effective.
Discussion
We used national representative data in Markov cohort models to estimate the impact on IHD
burden and health equity as well as the cost-effectiveness of a national ban of iTFA in Australia
compared to no ban and current levels of TFA intake. Our model estimated that elimination of
iTFA from the Australian food supply could prevent around 2,000 deaths and 10,000 incident
IHD-events over the first 10 years, with greater benefits among socioeconomically disadvan-
taged groups and Australians outside major cities. Across the population’s lifetime (i.e., the time
from policy implementation until all individuals died or reached 100 years of age), an iTFA ban
was estimated to avert nearly 42,000 IHD deaths. The intervention was estimated to be cost sav-
ing or cost-effective over the initial 10 years as well as over the population lifetime.
Fig 3. Total (A–B) and IHD-related (C–D) healthcare cost savings per capita estimated over 10 years (A, C) and population lifetime (B, D).
Estimates are presented separately for the total population and selected subgroups. Error bars represent 95% uncertainty intervals. AUD,
Australian dollar; IHD, ischemic heart disease; SEIFA, Socio-Economic Indexes for Areas.
https://doi.org/10.1371/journal.pmed.1003407.g003
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Interpretation and policy implications
Previous modelling studies have estimated the impact on cardiovascular disease burden of
plausible legal limits or bans of iTFA in the UK [26,29,35,36] and the EU [37]. In all of these
studies, such legislative policies were estimated to reduce the number of cardiovascular events
or deaths and/or increase HALYs or life years [38]. Three of the studies evaluated the cost-
effectiveness of bans or legal limits, taking into consideration health gains, healthcare cost
Fig 4. Relative inequality based on socioeconomic status in HALYs gained estimated over 10 years (A) and population lifetime (B).
Values above the dotted unity lines represent greater benefits among disadvantaged groups (i.e., lowest SEIFA ranking). Dots and error bars
indicate median and 2.5–97.5 percentiles of n = 2,000 estimates. The concentration index quantifies the distribution of HALY over
socioeconomic quantiles and takes a negative value when HALYs gained are disproportionally concentrated in the most disadvantaged
groups. HALY, health-adjusted life years; SEIFA, Socio-Economic Indexes for Areas; UI, uncertainty interval.
https://doi.org/10.1371/journal.pmed.1003407.g004
Table 3. HALYs gained by socioeconomic quintiles, absolute difference between extreme quintiles, and concentra-
tion index.




SEIFA-IRSD quintiles, HALYs gained
1 (most disadvantaged) 1,614 (1,276; 2,107) 22,512 (18,458; 30,830)
2 1,485 (1,181; 1,801) 21,528 (17,914; 25,147)
3 1,369 (1,099; 1,639) 23,105 (19,252; 26,771)
4 1,081 (881; 1,294) 20,486 (17,202; 23,833)
5 (most advantaged) 876 (714; 1,041) 18,014 (15,178; 20,776)
Difference between first and fifth quintiles, HALYs
gained
742 (357; 1,241) 4,648 (-491; 12,910)
Concentration index1 -0.119 (-0.172; -0.067) -0.040 (-0.101; 0.002)
HALY, health-adjusted life year; SEIFA-IRSD, Socio-Economic Indexes for Areas–Index of Relative Socio-Economic
Disadvantage; UI, uncertainty interval.
1The concentration index quantifies the distribution of HALY over socioeconomic quantiles and takes a negative
value when HALYs gained are disproportionally concentrated in the most disadvantaged groups.
https://doi.org/10.1371/journal.pmed.1003407.t003
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savings, and policy costs [26,29,37]. A legal limit of iTFA in the EU (assumed to remove all
iTFA) [37] and total bans in the UK [26,29] were estimated to be cost saving. Bans of iTFA in
the UK were also estimated to reduce health inequalities [26,29].
An important and novel aspect of our study is that the modelled population already has a
low average level of TFA intake (mean: 0.59%E). In previous modelling studies of different
strategies to reduce TFA intake in the UK and the EU [26,37], where average TFA intake is
higher (e.g., estimated TFA intake in the UK: 0.79%E [26]), it has been estimated that total
bans of iTFA across the food supply would be superior to other evaluated strategies (e.g., vol-
untary limits and mandatory labelling or TFA ban targeting restaurant and takeaway food)
with regard to health benefits and cost-effectiveness [26,37]. Our study builds on and signifi-
cantly extend these prior studies and suggest legislating to remove iTFA could still lead to
Fig 5. Net costs and HALYs gained during the first 10 years (A) and over the population lifetime (B) estimated in
the primary model and in deterministic sensitivity analyses. See Methods for descriptions of sensitivity analyses.
Dots represent estimates of n = 2,000 simulations, and ellipses indicate 95% confidence intervals centred around their
means. AUD, Australian dollar; HALY, health-adjusted life years; iTFA, industrial TFA.
https://doi.org/10.1371/journal.pmed.1003407.g005
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significant health benefits and be done in a highly cost-effective way, even in a population with
relative low average TFA intake like Australia. These findings support the WHO’s call to elimi-
nate TFA from the food supply around the world and strengthen the case that such a move
likely represents a public health ‘best-buy’ [6]. A ban of iTFA may be particularly beneficial in
certain Australian subpopulations where high TFA intakes (approximately 3%E) are possible
[12], and our modelling results comparing estimated benefits accrued among groups of differ-
ent social-economic circumstances and areas of residence support this assertion. These find-
ings are consistent with prior estimations that an iTFA ban would improve health equity [26]
due to the social economic gradient in iTFA consumption and burden of IHD. Experiences
from other countries suggest that legislating or other policy mechanisms to eliminate iTFA is
feasible. In Denmark, iTFA have been virtually eliminated after legislation introduced nearly 2
decades ago that limits the TFA content in food [7]. In the US, the Food and Drug Administra-
tion no longer considers partial hydrogenated oils to be generally recognized as safe (and
thereby not allowed in foods) [8]. Major food companies have also recently pledged to remove
iTFA from their products [39]. However, objective evaluations of similar voluntary actions by
the food industry suggest such commitments often fail or only partially achieve their goals
[40], and therefore, other mechanisms such as government legislation to ban iTFA may still be
required. An independent review on food labelling, commissioned by the Australian Govern-
ment in 2011, specifically recommended mandatory labelling of TFA if iTFA in foods were not
phased out by 2013 [41]. However, no such regulations have been implemented.
Strengths
Data used in our modelling were derived whenever possible from nationally representative
sources, increasing validity, and generalizability of the results. This include the use of data
from the most up-to-date, individual-level, nationally representative NNPAS. Data from a
meta-analysis of prospective studies directly linking consumption of TFA to incidence of IHD
were used instead of modelling a link mediated by blood lipids, and thus include potential
non-lipid-mediated effects of TFA intake such as inflammation, which may also account for
the harmful effect of TFA on IHD [42]. Healthcare costs estimated included both IHD-related
and other healthcare costs and thus allowed estimation of changes in total healthcare expendi-
tures. We estimated the health benefits and healthcare costs of eliminating iTFA among socio-
economic and urban–rural subgroups. We used SEIFA, which compared to income alone, is a
more comprehensive measure of relative socioeconomic advantage and disadvantage in Aus-
tralian population based on a wide range of socioeconomic indicators such as income, educa-
tion, employment, occupation, and housing, and thus may better assess social economic status
[43].
Limitations
The most recent nationally representative assessment of TFA intake was conducted nearly a
decade ago, and iTFA intake may have changed. However, there has been no government pol-
icy or mandate to reduce iTFA in the last 2 decades [10]; iTFA content in food products has
been largely similar between 2005 and 2013 [10], and TFA intake remained stable from 1995
to 2012 [4]. This suggests that it is reasonable to assume fairly stable TFA intake levels since
2012. The number of products potentially containing iTFA were identified using the 2018
FoodSwitch database, and it is possible that the number of identified products would be
greater if assessed concomitantly with the NNPAS in 2012. However, in the absence of policy
and active government engagement with food industry in Australia, there is little reason to sus-
pect that the number of products with iTFA has changed substantially in the food supply over
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recent years, and in sensitivity analyses, doubling the number of products with iTFA did not
materially impact our findings. The sample size of some age and sex groups was small (e.g.,
Australian outside major cities and inner regional areas), which may have resulted in impre-
cisely estimated means and standard deviations of TFA intake, especially in the subgroups
analyses.
Consistent with prior modelling papers, our model uses risk estimates of change in TFA
against the overall diet rather than specific substitution with other types of fats. If the iTFA
would be systematically replaced by saturated fatty acids, the impact of the ban could be lower
than estimated here. However, evidence suggest no overall increase in saturated fatty acid con-
tent in food products after previous reductions of iTFA [10]. Indirect costs, e.g., productivity
loss due to absenteeism or disability, were not included in the estimation of healthcare cost
savings, which means that the societal savings from the intervention are likely to be substan-
tially underestimated. When Australia-specific cost data were not available, we used costing
frameworks from the UK and New Zealand, which may under or overestimate such costs. Our
modelling study does not prove that a ban of iTFA will prevent IHD; rather, it provides impor-
tant quantitative estimates, corresponding uncertainty, and assessments of sensitivity of the
findings to different inputs, resulting in a range of plausible effects on IHD burden and cost-
effectiveness of legislating an iTFA ban in Australia to help inform policy makers.
Conclusions
Our model estimates suggest that a ban of iTFAs, compared to no ban and current TFA intake,
could be a highly cost-effective strategy to reduce the Australian IHD burden and could lead to
tens of thousands of prevented premature deaths. Introducing such a policy was also estimated
to reduce social–economic and urban–rural inequalities in IHD disease burden over the first
10 years.
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